Dissociative anesthetic, FDA-approved (as Spravato) for treatment-resistant depression.
Ketamine is a synthetic compound first produced in 1962 by Parke-Davis chemist Calvin Stevens and introduced into US clinical use in 1970 as a general anesthetic.1 Pharmacologically, it is a non-competitive antagonist of the NMDA glutamate receptor — meaning it works on a completely different neurotransmitter system than the "classic" psychedelics (psilocybin, LSD, DMT), which act primarily as 5-HT2A serotonin receptor agonists. For that reason, many researchers classify ketamine as a "dissociative anesthetic" rather than a psychedelic proper. In therapeutic use the two categories overlap enough that most clinicians and policymakers treat ketamine as part of the same conversation.
Technically, no — but practically, it belongs in the same conversation. Ketamine is a dissociative anesthetic. It works on the NMDA glutamate receptor, not the serotonin 5-HT2A receptor that psilocybin and LSD activate. At sub-anesthetic therapeutic doses, it does produce dissociation, perceptual changes, and experiences users often describe as "psychedelic." The FDA, DEA, and most clinical researchers treat ketamine separately from classical psychedelics because its scheduling (Schedule III, not Schedule I) and clinical approval pathway differ.
Yes — and also a human anesthetic used in surgery, emergency medicine, and pediatric care worldwide since 1970. Ketamine is FDA-approved for use in humans and has been a first-line anesthetic in emergency departments and field medicine for decades. Its use in veterinary medicine, including equine practice, is real but secondary to its established human medical role. The "horse tranquilizer" description is accurate but incomplete — it has been standard human medicine far longer.
There are three distinct access models in the US today, and they are not interchangeable:
| Model | What happens | Typical cost per session | Insurance |
|---|---|---|---|
| In-clinic IV infusion | 0.5 mg/kg over ~40 minutes, monitored by anesthesia-trained staff. Most research uses this route. | $400–$800 | Rarely covered for depression; sometimes covered for chronic pain. |
| Spravato (esketamine) nasal spray | FDA-approved 2019 for treatment-resistant depression, 2020 for MDD with suicidal ideation. Self-administered in a certified office under 2-hour observation.2 | $590–$885 (drug) + clinic observation | Frequently covered; REMS program required. |
| At-home oral lozenges (telehealth) | Compounded rapid-dissolve troches, prescribed after a telehealth psychiatric visit. Patient self-administers at home. | $150–$400/month | Not covered; paid out-of-pocket. |
The debate is mostly about supervision, not about the molecule. Both at-home and in-clinic ketamine deliver the same Schedule III compound. What differs is who is watching, what happens if something goes wrong, and what the evidence base is for each setting.
| Factor | At-home oral (telehealth) | In-clinic IV/IM |
|---|---|---|
| Safety monitoring | Patient is alone or with a sitter; no real-time vital signs. Emergency response is caller-initiated. | Clinical staff present; blood pressure, heart rate, and oxygen monitored throughout. IV can be stopped immediately. |
| Dose form and bioavailability | Oral lozenges (sublingual absorption); bioavailability ~25–30%. Dose must be higher to compensate. | IV is 100% bioavailable; IM ~90%. Clinical trials almost exclusively used these routes. |
| Evidence base | Little direct RCT evidence for the telehealth model. Extrapolated from IV/IM studies; real-world outcomes data is emerging. | Decades of peer-reviewed trials; FDA-registration trials for Spravato used the in-office model. |
| Typical cost | $150–$400/month all-in. Lowest price point of any ketamine access model. | $400–$800 per session; 6-session induction = $2,400–$4,800. |
| Insurance | Not covered. HSA/FSA may apply. | Rarely covered for depression; Spravato (in-office only) is frequently covered. |
| Quality variance | Very high. Program quality ranges from rigorous psychiatric evaluation to a 10-minute form. Screening and follow-up protocols vary widely. | Moderate. Clinic quality varies but in-person setup requires staffing and licensing that creates a baseline floor. |
| Best for | Lower-risk patients with stable mental health history, strong support at home, and no contraindications. Use the at-home safety checklist before committing. | Patients with complex history, higher acuity, or who want the most-studied administration model. Required for Spravato. |
The first two models in the earlier table (IV and Spravato) are evidence-based and REMS-supervised. The third — at-home telehealth — is the fastest-growing and the most regulated-grey: it was enabled by DEA telehealth flexibilities during COVID-19 and tightened substantially after the 2023 death of actor Matthew Perry, which was ruled to involve ketamine obtained outside his then-active clinic program.
The foundational finding — a rapid antidepressant effect within hours of a single sub-anesthetic dose — was reported by Berman et al. in 2000.3 That effect has been replicated dozens of times since. A 2023 meta-analysis in the British Journal of Psychiatry of 36 trials found that ketamine produced significantly greater antidepressant response than placebo through 72 hours, with effect sizes larger than conventional antidepressants.4
The harder question is durability. A single infusion's benefit typically fades within days to weeks. Spravato's pivotal SUSTAIN-1 maintenance trial demonstrated that repeat dosing every 1–2 weeks reduced relapse versus placebo, which is the basis for its current dosing schedule.5 How long the durability effect persists after discontinuation is an active research question.
A 2020 Phase 3 trial (ASPIRE-I) led to Spravato's 2020 expanded indication for major depressive disorder with acute suicidal ideation or behavior — a patient population conventional antidepressants serve poorly because they take weeks to work. Ketamine's hours-scale onset is the entire clinical argument.
They work through different mechanisms and usually aren’t a head-to-head choice. EMDR (Eye Movement Desensitization and Reprocessing) is a structured, drug-free talk therapy that uses bilateral eye movements to help reprocess traumatic memories over multiple sessions. Ketamine works pharmacologically — it triggers a burst of glutamate-driven synaptic growth that can rapidly lift depression and, in some protocols, widen a window of psychological flexibility that makes trauma processing easier. Some clinicians use the two sequentially (ketamine to break a depressive episode, EMDR to do the trauma-processing work), but no head-to-head trials compare them directly, so neither approach can be called more effective than the other from the evidence alone.
Not as a standard offering. The overwhelming majority of ketamine programs — in-clinic infusion centers, Spravato REMS clinics, and at-home telehealth alike — treat one patient at a time with individualized dosing and monitoring, because the acute dissociative effects require dedicated clinical attention. If a provider markets shared or simultaneous "couples" dosing sessions, vet them the same way you’d vet any provider (medical screening, licensed supervision, a clear plan if something goes wrong) before assuming the format is standard practice.
Chronic-use concerns are the more important long-term question, and the reason reputable clinics push back against high-frequency at-home protocols:
Contraindications include uncontrolled hypertension, recent cardiovascular events, active psychosis, and pregnancy.
Ketamine is a Schedule III controlled substance under the US Controlled Substances Act — the same schedule as buprenorphine and anabolic steroids. That makes it the only US-legal option among the therapies in this catalog. Two federal frameworks govern clinical use: the DEA's Schedule III prescribing rules, and the FDA's REMS program for Spravato specifically.
State-level law matters for telehealth: the DEA's flexibilities on remote controlled-substance prescribing (inherited from the COVID-19 public health emergency) have been repeatedly extended. Changes here directly affect whether at-home oral ketamine remains available through telehealth-only providers — one of the policy developments we track on analysis.
Yes — ketamine is legal in the United States when prescribed by a licensed clinician. It is a Schedule III controlled substance that the FDA approved as an anesthetic in 1970, which makes it legal to prescribe nationwide. Its derivative, esketamine (Spravato), is FDA-approved for treatment-resistant depression and is delivered under a restricted REMS program. The widely used ketamine-for-depression treatments — IV/IM infusions and at-home oral ketamine — are legal off-label prescriptions: the drug is approved, and physicians may prescribe an approved drug for an unapproved use. What is not legal is recreational possession or buying ketamine without a prescription. This is the key reason ketamine is the only psychedelic-adjacent therapy you can legally access in all 50 states today, while psilocybin and MDMA remain Schedule I outside of clinical trials and a handful of state programs.
For a practical next-step comparison of Spravato, IV/IM ketamine, at-home oral ketamine, and psilocybin access for depression, see the depression treatment path.
If cost is a barrier: start by asking whether your insurance covers Spravato for treatment-resistant depression. That is the path with the most regulatory guardrails and the most insurance support. The REMS program requires that you take it in a certified provider's office under observation — there's no home version.
If you want the most-studied intervention: IV infusion at a clinic run by an anesthesiologist or psychiatrist with anesthesiology backup. Ask explicitly about protocols, screening, and follow-up. Most research trials use the 0.5 mg/kg over 40 minutes infusion protocol — clinics that deviate sharply from that warrant extra scrutiny.
If you are considering telehealth at-home: verify that the prescribing clinician is licensed in your state, has a real psychiatric evaluation process (not a 10-minute form), and includes integration / follow-up care. The telehealth model is the one where the quality variance across providers is largest. Use the at-home ketamine safety checklist before any program ships medication.
Insurance coverage for ketamine therapy depends entirely on which form you receive. Spravato (esketamine) is the only form with meaningful coverage. Many major health plans — including some Blue Cross Blue Shield, Aetna, and UnitedHealthcare plans — cover Spravato for patients who meet the treatment-resistant depression criteria (typically two or more failed antidepressant trials). Because Spravato is FDA-approved, it has a billing code insurers recognize.
Off-label IV, IM, and sublingual ketamine is almost always out of pocket. Most insurers do not cover it because it lacks FDA approval for depression specifically. A typical IV infusion costs $400–$800 per session, and an induction course of six sessions runs $2,400–$4,800 before any maintenance. Sublingual lozenges from telehealth providers typically run $150–$400 per month.
What you can still use: off-label ketamine often qualifies for HSA and FSA reimbursement as a medical expense. Some clinics provide a superbill (an itemized receipt with diagnosis and procedure codes) so you can submit to insurance for partial out-of-network reimbursement — ask your provider before the first session whether they do this.
For a detailed comparison of Spravato vs IV ketamine insurance coverage and cost, see the depression treatment path.
At-home telehealth ketamine is the most affordable legal ketamine option in the US. The table below compares the leading providers by monthly cost, dose model, and whether integration therapy is included in the base price. Costs are approximate — verify with each provider before enrolling.
| Provider | Dose model | Therapy included | Approx. monthly cost | Published outcomes? |
|---|---|---|---|---|
| Joyous | Microdose (daily, sub-perceptual) | No (app support) | ~$129–$169/mo | Yes — observational study (n=1,247) |
| Mindbloom | Full-dose (sublingual) | Optional add-on | ~$198–$268/mo | Yes — internal data published |
| Nue Life Health | Full-dose | Yes — prep + integration | ~$250–$350/mo | Preliminary (not peer-reviewed) |
| Wondermed | Full-dose | No | ~$220–$280/kit | Limited |
| Klinic | Full-dose | No (referral only) | ~$180–$250/mo | Limited |
For a head-to-head comparison of these providers with more clinical detail — including screening protocols and outcomes data — see our online ketamine therapy providers guide. For veterans specifically, our ketamine therapy for veterans guide covers VETS grants, VA Spravato coverage, and veteran-discounted programs.
Ketamine therapy feels different from most medical treatments. At therapeutic doses, the drug produces a dissociative state — you remain conscious but feel detached from your surroundings, as if floating or dreaming.
During an IV session: a nurse or anesthesiologist administers the infusion over 40 minutes (the most common protocol uses 0.5 mg/kg). Most people feel the effects within 5–10 minutes. The dissociation can include altered visual perception, a sense of distance from the room, and occasionally vivid imagery. The clinical term is a "dissociative anesthetic" — not a hallucination in the classical sense, but not an ordinary state either. It ends within 30–60 minutes of the infusion stopping.
Does ketamine therapy get you high? At therapeutic doses, yes — there is an acute subjective effect. This is different from recreational misuse: therapeutic doses are sub-anesthetic, carefully titrated, and administered in a clinical setting with monitoring. The acute effect is not the treatment itself; current research suggests the antidepressant benefit comes from the downstream neuroplasticity changes the drug triggers, not from the experience of dissociation.
How many sessions? Most initial courses run six infusions over two to three weeks. This is the schedule used in the majority of clinical research. After the induction course, some patients maintain benefit for weeks to months; others need monthly or bi-monthly maintenance sessions. Telehealth sublingual programs vary — they typically involve a longer, lower-intensity protocol with lozenges taken weekly or bi-weekly.
Outcomes across all three access models correlate with whether the patient has a therapist working alongside the medical prescriber. This is the part of the treatment the FDA does not directly regulate — it is "off-label" but evidence-supported. See the integration therapy guide for what a good integration relationship looks like and how to find one.
Ketamine therapy has been covered in mainstream media including the Hulu series The Secret Lives of Mormon Wives. Our editorial commentary on that coverage explains what the show got right and what the medical context it compressed.
Get ketamine research & policy updates
New trials, FDA decisions, and legal changes for ketamine — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.